Over halfway through the trading day on Tuesday, and the broad markets have yet to make up their minds. For the most part, the S&P 500 and Dow Jones industrial average have been trading sideways, albeit a little negative. The Nasdaq has picked up slightly, and the Russell 2000 is having the best showing out of the group.

With Congress finally coming to a consensus about another round of stimulus for the economy, investors would think that markets would be rallying on this positive news. However, Tuesday has proven to be a real stock-picker’s day.

To help divine which stocks could be rising or falling as a result of these developments, 24/7 Wall St. is taking a look at some big analyst calls that we have seen so far today. We have included the most recent analyst call on the stock, as well as a recent trading history and the general consensus among analysts.

For those that might have missed it, 24/7 Wall St. had an earlier round of analysts calls on Tuesday.

Biogen Inc. (NASDAQ: BIIB) was maintained as Buy at Canaccord Genuity. However, the firm did cut its price target to $359 from $393. The consensus price target is $291.40. Biogen stock was last seen trading at $248.08, in a 52-week range of $223.25 to $374.99.

Healthpeak Properties Inc. (NYSE: PEAK) was reiterated as Buy at Stifel with a $34 price target. The consensus price target is $30.56, and the stock was trading at $29.64. The 52-week range is $18.63 to $37.64.

IQVIA Holdings Inc. (NYSE: IQV) was reiterated at Stifel with a Buy rating and a $227 price target, compared to the most recent closing price of $176.75. The stock has traded in a range of $81.79 to $180.99 over the past 52 weeks. The consensus price target is $199.89.

Leslie’s Inc. (NASDAQ: LESL) was reiterated with a Buy rating and a $29 price target at Jefferies. The brokerage firm noted that Leslie’s is looking to build its outlook on what has been a record year. The stock was recently trading at $24.31, with a 52-week range of $19.15 to $25.84. Analysts have a consensus price target of $24.78.

Lockheed Martin Corp. (NYSE: LMT) was reiterated as Hold by Jefferies and given a $400 price target, implying upside of 14% from the most recent closing price of $349.35. The consensus price target is $435.74. Lockheed Martin stock traded at $348.95, in its 52-week range of $266.11 to $442.53.

Kratos Defense & Security Solutions Inc. (NASDAQ: KTOS) was reiterated with a Buy rating and a $23 price target. Shares were trading at $26.12, with a consensus price target of $25.40. The stock has traded in a range of $5.00 to $26.90 over the past 52 weeks.

Peloton Interactive Inc. (NASDAQ: PTON) was reiterated as Outperform and its price target was raised to $162 from $142 at JMP Securities. Shares of Peloton were up 13% at $163.39, in a 52-week range of $17.70 to $166.23. The consensus price target is $136.33.

Square Inc. (NYSE: SQ) was reiterated with a Buy rating at BTIG Research, which also raised the price target to $295 from $220. Square stock was up about 2% at $237.54, with a consensus price target of $200.00. The stock has traded within a range of $32.33 to $242.58 over the past year.

Veeva Systems Inc. (NYSE: VEEV) was reiterated with a Buy rating and a $325 price target at Stifel. This compares with a consensus price target of $308.43. Veeva stock was up about 5% at 284.04, and it has a 52-week range of $118.11 to $313.99.

Ventas Inc. (NYSE: VTR) was reiterated with a Hold rating and a $47 price target at Stifel. This implies nearly a 4% downside from the most recent closing price of $48.83. The stock has a consensus price target of $46.37 and a 52-week range of $13.35 to $63.38.

Five top semiconductor companies not only have a long history of success and innovation, but their stocks still offer a reasonable upside to the Goldman Sachs 2021 price targets.

Also check out some of the biggest IPO losers of 2020, several of which came public before the pandemic hit.

Get Our Free Investment Newsletter

I have read, and agree to the Terms of Use

Thank you for reading! Have some feedback for us?
Contact the 24/7 Wall St. editorial team.